# Revvity, Inc. (RVTY) — Stock CV

Revvity, Inc. is a $17.2B technology company. Revenue grew 4.1% over the last year, it keeps 8¢ of every dollar of sales as profit, and its net debt equals ~3.1 years of free cash flow. It trades at 72.4× earnings — near the highest of its own history.

> Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer.

## Identity

- **Ticker**: RVTY
- **Sector**: Technology
- **Industry**: Laboratory Analytical Instruments
- **Headquarters**: WALTHAM, MA
- **Employees**: 11 000
- **Website**: https://www.revvity.com
- **Market cap**: $17.2B
- **Last price**: $154.18
- **Financial profile**: Strained

## Vitals (TTM)

- **Revenue**: $2.91B
- **Net income**: $238M
- **Free cash flow**: $558M
- **Net debt**: $1.71B
- **P/E**: 72.4
- **Revenue growth (YoY)**: 4.1%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 29 |
| Growth | 25 |
| Profitability | 35 |
| Health | 40 |
| Quality | 77 |
| Moat | 68 |

## Qualifications (beginner checklist) — 8 of 11 passed

- [x] Revenue growing — +4.1% YoY
- [x] Profitable — $238M TTM
- [ ] Profit growing — -22.8% YoY
- [x] Generates cash — $558M TTM
- [x] Debt under control — ~3.1y of cash flow to repay
- [x] Established company — $17.2B market cap
- [x] Not printing shares — +3.3% shares over ~5y
- [x] Proven track record — 5/5 profitable years
- [ ] Financially stable — health score 28/100
- [x] Pays a dividend — yield 0.18%
- [ ] Valuation not extreme — P/E 72.4

## Experience (career milestones)

- **2026** — Revvity Signals Software business announced it joined Anthropic's directory for Model Context Protocol…
- **2025** — Revvity’s Euroimmun launched the IDS i20 analytical random access platform, enabling full automation of…
- **2023** — Revvity's Euroimmun business received CE-IVDR certification for the UNIQO 160, an automated indirect…
- **FY2021** — Profitable every year on record: 5 consecutive profitable years in our data
- **FY2021** — Revenue already above $1B: $3.83B in first reported year
- **FY2021** — Positive free cash flow every year since: 5-year streak
- **FY2021** — Best year on record: $943M net income

## Strengths

- High gross margin (55.0%)
- Strong cash conversion — FCF is 19.2% of revenue

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $3.83B | $943M | $1.32B |
| FY2022 | $3.31B | $569M | $594M |
| FY2023 | $2.75B | $693M | $9.90M |
| FY2024 | $2.76B | $270M | $542M |
| FY2025 | $2.86B | $241M | $509M |

---

Source: https://stockcv.com/RVTY — derived from company filings; may be delayed or incomplete. Information, not investment advice.